Company news
Arovella Therapeutics Limited (ASX:ALA) news
Arovella Therapeutics Limited news releases on 6ix. Latest, Sep 24, 2019: Manaing Director and CEO Resignation
Press releases — page 3
Manaing Director and CEO Resignation
September 23, 2019
ArTiMist Appeal Lodged With TGA
August 8, 2019
ZolpiMist Clinical Results Published
August 6, 2019
European Anagrelide Cancer Patent
July 21, 2019
Supplementary Prospectus
June 27, 2019
Rights Issue Closes Significantly Oversubscribed
June 25, 2019
SUDA SIgns Binding Term Sheet With Cann Pharmaceutical
June 4, 2019
Prospectus For Renounceable Pro Rata Offer
June 2, 2019
Product Development Market Update
May 12, 2019
ArTiMist Regulatory Update
April 18, 2019
Appendix 4C Amended
February 4, 2019
SUDA Signs Agreement With Mitsubishi Tanabe
December 18, 2018
ZLD to Invest in Development of Oral Spray Formulations
December 5, 2018
SUDA Receives R&D Tax Incentive Refund
November 14, 2018
ZolpiMist Market Update
November 12, 2018
SUDA Signs Agreement For SUD-001H For US Market
November 7, 2018
Appendix 4C, Market Update and Top 20
October 28, 2018
Request for Trading Halt
September 11, 2018
SUDA Achieves TGA GMP Licence
August 20, 2018
Business Development Update
July 15, 2018
Anagrelide Update
July 11, 2018
Prospectus for a Renounceable Pro Rata Offer
July 1, 2018
Shareholder Update
June 20, 2018
SUDA Expands Patent Coverage For Sildenafil
June 17, 2018
SUDA announces update on ZolpiMist in USA and Canada
June 15, 2018
SUDA expands dialogue with World Health Organisation
May 7, 2018
HC Berlin Pharma Update
May 1, 2018
SUDA Completes Divestment of Subsidiary
March 7, 2018
Divestment Of Non-Core Subsidiary
February 26, 2018
New Analyst Report
February 15, 2018
SUDA Completes Acquisition Of Anti-Cancer Agent
January 23, 2018
SUDAs Licensee Submits Marketing Application
December 5, 2017
SUDA Acquires Novel Oro-Mucosal Anti-Cancer Agent
November 27, 2017
SUDA Publishes Amended Shareholder Newsletter
September 12, 2017
SUDA Achieves ISO Accreditation
July 30, 2017
Strong Revenue Growth for SUDA Subsidiary
July 23, 2017
SUDA Enters Licence Agreement With Teva
July 4, 2017
SUDA Signs Term Sheet To Acquire Anti-Cancer Agent
June 20, 2017
SUDA Meeting For Zolpimist Into Europe
May 25, 2017
Placement, Interest Shares and Convertible Note Prospectus
April 24, 2017
SUDA Completes $1.5m Capital Raising
April 6, 2017
SUDA Submits Application For ArTiMist
April 3, 2017
SUDA Extends Maturity of Convertible Notes
April 2, 2017
SUDA Enters Feasibility Agreement With Pfizer
March 29, 2017
SUDA expands patent coverage for SUD-003 and SUD-004
March 2, 2017
SUDA Announces Strong Revenue For Westcoast
February 27, 2017
Reinstatement to official quotation
February 26, 2017
Suspension from official quotation
January 26, 2017
SUDA presents data on novel technology
November 17, 2016
SUDA Enters Licensing Agreement For ZolpiMist in China
November 8, 2016